Second-generation antipsychotics for schizophrenia: A review of clinical pharmacology and medication-associated side effects

Israel Journal of Psychiatry and Related Sciences

Volumn 42, Issue 1, 2005, Pages 51-60

  Conley, Robert R ^a   Kelly, Deanna L ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23844556154     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999;40:407-414.
2. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10:105-114.
3. Sedvall GC. Neurobiological correlates of acute neuroleptic treatment. Int Clin Psychopharmacol 1996;11:41-46.
4. Soubrie P, Reisine TD, Glowinski J. Functional aspects of serotonin transmission in the basal ganglia: A review and an in vivo approach using the push-pull cannula technique. Neuroscience 1984;131:615-624.
5. IMS Health, Retail & Provider Perspective, December 2002.
6. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmar C, Mintz J, Liberman RP, Blair KE. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160:1405-1412.
7. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Shama T, Zipursky R, Wei H, Hamer RM, HGDH study group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404.
8. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: A systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376.
9. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand 1994;89:11-15.
10. th edition. Medical Economics Company, Inc., Montvale, NJ, 2003.
11. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;27:1841-1845.
12. Klimke A, Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. Am J Psychiatry 1994;151:780.
13. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
14. Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46;73-77.
15. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
16. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113.
17. Taylor DM. Aripiprazole: A review of its pharmacology and clinical use. Int J Clin Pract 2003;57:49-54.
18. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
19. Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 2002;17:263-264.
20. Yovtcheva SP, Stanley-Tilt C, Moles JK. Reemergence of tardive dyskinesia after discontinuation of clozapine treatment. Schizophr Res 2000;46:107-109.
21. Uzun O, Cansever A, Ozsahin A. A case of relapsed tardive dyskinesia due to clozapine dose reduction. Int Clin Psychopharmacol 2001;16:369-371.
22. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63:12-9.
23. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000;15:506-514
24. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caliguiri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719.
25. Aronne LJ. Epidemiology, morbidity and treatment of overweight and obesity. J Clin Psychiatry 2001;62:13-22.
26. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001;62 9:22-31.
27. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer HJ, Fleischhacker W. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-440.
28. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58:45-49.
29. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100.
30. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262.
31. Csernansky JG, Mahmoud R, Brenner R, the risperidone USA-79 study group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
32. Brecher M, Rak IW, Westhead EK, et al. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-292.
33. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-523.
34. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, AIi M, Archibald D, Ingenito G, Marcus R, Pigott T. Int J Neuropsychopharmacol 2003;6:325-337.
35. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62:15-26.
36. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32.
37. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
38. Koro CE, Fedder DO, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. BMJ 2002:325-331.
39. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:79-81.
40. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-981.
41. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 1999;156:1471-1472.
42. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
43. Koro CE, Fedder DO, Weiss S, Magder LS, Italien GJ, Kreyenbuhl J, Revicki D, Buchanan RW. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-1026.
44. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62:27-34.
45. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. J Clin Psychiatry 2003;64:1133-1134.
46. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.
47. Burns T, Floritti A, Holloway F, Malm U, Rossler W. Case management and assertive community treatment in Europe. Psychiatr Serv 2001;52:631-636.
48. Ghadirian AM, Chouinard G, Annable, L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic patients. J Nerv Ment Dis 1982;170:463-467.
49. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992;22:305-327.
50. Wilson CA. Pharmacological targets for the control of male and female sexual behaviour. In: Riley AJ, Peet M, Wilson C, editors. Sexual pharmacology. Oxford: Oxford Medical Publications, 1993: pp. 1-58.
51. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Anderson SW, Beasley C, Jr., Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
52. Bobes J, Garc A-Portilla MP, Rejas J, Hernandez G, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE group. J Sex Marital Ther 2003;29:125-47.
53. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-135.
54. Peacock L, Solgard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics: Effects and side effects. Neuropsychopharmacol 1994;10:223-354.
55. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61.
56. Mullen B, Brar JS, Vagnucci AH, Ganguli R. Frequency of sexual dysfunction in patients with schizophrenia on haloperidol, clozapine, or risperidone. Schizophr Res 2001;48:155-158.
57. Crawford AMK, Beasley CM Jr., Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
58. Arvenitis L, Miller B, Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.